BioSpace News Archive

Bio-Techne Corporation announced that it will present at the following investor healthcare conferences.

Abata Therapeutics, a company focused on translating the biology of regulatory T cells into transformational medicines for patients living with severe autoimmune and inflammatory diseases, announced that company leadership will present and participate in the following investor and industry events.

OneOncology, the fastest-growing national platform for independent practices, announced it has finalized 25 unique oncology and hematology pathways and published each pathway inside the platform’s clinical decision support tool.

Centene Corporation announced that it has signed a definitive agreement to sell Circle Health Group, one of the U.K.'s largest independent operators of hospitals, to PureHealth, the largest integrated healthcare network in the Middle East.

NLS Pharmaceutics Ltd. announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders.

HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies.

SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, announced that management will participate in the following investor conferences.

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced details of three presentations given from studies of NE3107 in the treatment of Parkinson’s Disease (PD) at the 2023 International Congress of Parkinson’s Disease and Movement Disorders (MDS), being held in Copenhagen, Denmark August 27-31, 2023.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to provide shareholders with an update on recent progress in the development of BeaMed’s groundbreaking StingRay Laser System (the “System”).

IceCure Medical Ltd. developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced the appointment of Mr. Shad Good, a seasoned healthcare executive, as Vice President of Sales for North America.